Mike Waring, Editor-in-chief
Newcastle University
Mike Waring is Chair of Medicinal Chemistry at Newcastle University and Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit. He was previously Principal Scientist in Medicinal Chemistry at AstraZeneca. He has worked mainly in the areas of diabetes and oncology and his work has contributed to the discovery of 14 drug candidates, including the marketed EGFR inhibitor osimertinib (Tagrisso™).
He has made significant contributions to the field in many areas, perhaps most notably property-based optimisation, covalent inhibition, novel binding modes and new methods of hit generation. He is a 2018 American Chemical Society Hero of Chemistry and recipient of the 2017 RSC Malcolm Campbell Medal. He is an elected fellow of the 蹤獲扦.
Cynthia Dowd, Associate editor
George Washington University, USA
Dr. Cynthia Dowd is a Professor of Chemistry at George Washington University. She obtained a BA in Chemistry from the University of Virginia and a PhD in Medicinal Chemistry from Virginia Commonwealth University (with Dr. Richard Glennon). Following a postdoc at the University of Pennsylvania (with Dr. Irwin Chaiken), Cindy was an intramural scientist at the National Institutes of Health (NIH). There, she led a small molecule chemistry group to discover novel agents against tuberculosis.
In 2007, she began her independent career at GWU where her research is focused on the design and synthesis of novel antiinfective therapies, directed primarily against tuberculosis, malaria and the ESKAPE pathogens.
She is the co-author of many peer-reviewed papers, patents, reviews, and book chapters. She is the recipient of the GWU Bender teaching and DREAM mentorship awards, as well as several large research awards from outside institutions.
Maria Duca, Associate editor
Université Côte d’Azur - CNRS, France
Dr. Maria Duca is head of Targeting of Nucleic Acids research group in the Institute of Chemistry of Nice (Université Côte d’Azur - CNRS). After undergraduate studies in Pharmacy and Medicinal Chemistry (Faculty of Pharmacy, University of Bologna, Italy), she obtained her PhD in Molecular Biochemistry under the supervision of Dr. Paola B. Arimondo (National Natural History Museum, Paris, France) working on topoisomerase II inhibitors. A 2- year post-doctoral training in Sydney Hecht’s lab (Department of Chemistry, University of Virginia, USA) allowed her to pursue the study of nucleic acids working on targeted protein mutagenesis upon chemical modification of tRNAs. After CNRS recruitment as a Research Scientist in 2007, her research activities focus on the targeting of non-coding RNAs using synthetic small molecules toward innovative therapeutic approaches for anticancer, antiviral and antimicrobial applications.
Sankar K. Guchhait, Associate editor
National Institute of Pharmaceutical Education and Research (NIPER), India
Sankar K. Guchhait is a Professor in the Department of Medicinal Chemistry at the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India. He did his PhD research at the Indian Association for the Cultivation of Science (IACS), Kolkata. Following his postdoctoral research for four years at the University of Tennessee, Knoxville, the University of Illinois at Chicago, and the University of California, Riverside, he started his research and teaching career at NIPER in 2007.
His research focuses majorly on medicinal chemistry, anticancer drug discovery, and synthesis of natural product-based and pharmaceutically important heterocyclic compounds. The research activities in his group made significant contributions to areas, especially medicinal chemistry strategies - Natural product-inspired, Scaffold-hopping, and Choice-based change approaches, Molecular medicinal insights, creating a new from clinical trial agents and drugs, and identification of target-specific unique pharmacophore motifs.
He is the recipient of several honors and awards, such as the Chemical Research Society of India (CRSI) Bronze Medal in 2022 and the Indian Chemical Society's Professor D. Nasipuri Memorial Award in 2015.
Susanne Müller-Knapp, Associate editor
Goethe University Frankfurt, Germany
Susanne Müller-Knapp is Chief Operating Officer at the Structural Genomics Consortium, SGC, Frankfurt and Director of Operations of the Chemical Probes Portal. She obtained a PhD at the Karolinska Institute in Stockholm, Sweden. After spending several years as postdoctoral researcher in the area of inflammation and gene regulation at the Karolinska Institute and at the DIBIT San Raffaele Scientific Institute in Milan, Italy, she joined 2004 the Structural Genomics Consortium (SGC), at Oxford University, where she coordinated the Epigenetic Probe Project and lead a group, focusing on the evaluation of novel chemical probes, cellular target engagement of these tool compounds and their biological roles. Her research now focuses on using chemical biology to dissect the role of specific targets in biology and disease with a main focus on cancer. In her role as Director of Operations for the Chemical Probes Portal, she focuses on providing data and knowledge on high quality chemical tools and establishing quality standards for chemical probes with diverse modes of action.
Sally-Ann Poulsen, Associate editor
Griffith University, Queensland, Australia
Sally-Ann Poulsen is Professor and Deputy Director (acting) at Griffith Institute for Drug Discovery (GRIDD), Griffith University, Brisbane, Australia. She holds a PhD in medicinal chemistry also from Griffith University, receiving a University Medal for academic excellence.
Immediately following her PhD she was recipient of a Royal Society & National Health and Medical Research Council (NHMRC) Howard Florey Research Fellowship to undertake research at the University of Cambridge. On returning to Australia, she was awarded an Australian Research Council QEII Fellowship, followed by an Australian Research Council Future Fellowship.
Sally-Ann works with collaborators in Australia and internationally, both from academia and industry on projects related to the development of new chemical probes, medicinal chemistry targeting cancer and infectious disease, and fragment screening using native state mass spectrometry. Her research is defined by the application of chemistry expertise to address complex questions across biology.
She was appointed as a Fellow of the Royal Australian Chemical Institute (RACI) in 2017. She is Chair-elect of the RACI Medicinal Chemistry and Chemical Biology Division and is a global council member of the International Chemical Biology Society. She is the author of more than one hundred publications in the field of medicinal chemistry and chemical biology.
Jian Zhang, Associate editor
Shanghai Jiao Tong University School of Medicine, China
Jian Zhang is a Distinguished Professor and Head of the Medicinal Chemistry & Bioinformatics Center at Shanghai Jiaotong University School of Medicine. In addition, he is also Dean of the School of Pharmacy at Ningxia Medical University, a member of the Academic Degrees Committee of the State Council in China, and founder of Nutshell Therapeutics.
In the last decade, his research has been concerned with drug design, medicinal chemistry and chemical biology, especially target identification and first-in-class allosteric drug discovery.
Hayley Binch
Hoffman-La Roche, Switzerland
Dr Hayley Binch is Head of Medicinal Chemistry at Hoffmann-La Roche in Basel. She obtained her PhD at the University of Bristol, UK in the field of Organic Chemistry, followed by postdoctoral research at the University of Hamburg, Germany and King’s College London. In 1998, she joined the Medicinal Chemistry department of Vertex Pharmaceuticals, Oxford, focussing on kinase research in the field of Oncology. In 2006, she moved to Vertex San Diego to work on ion channels for pain and cystic fibrosis. In 2016, she joined as a Section Head within Medicinal Chemistry at Hoffmann-La Roche in Basel and subsequently became Head of Medicinal Chemistry in 2017.
At Roche, the Medicinal Chemistry department supports the design and synthesis of small molecules to identify clinical candidates in the areas of Immunology, Infectious Diseases, Neuroscience, Oncology, Ophthalmology and Rare Diseases.
Paola Castaldi
MatchPoint Therapeutics, USA
Paola Castaldi is an experienced and passionate chemical biologist with experience in leading multidisciplinary teams supporting programs across several therapeutic areas and stages. Her drive towards embedding state-of-the-art technologies in drug discovery and development resulted in several contributions to target identification, mechanism of action and safety deconvolution of therapeutics.
Before joining LifeMine Therapeutics, Paola headed the Chemical Biology & Proteomics department at AstraZeneca. Over the years Paola was responsible for the build of a state-of-the-art chemical biology and mass spectrometry hub with global impact across all therapeutic areas and platforms. Notably, she played a critical role to the establishment of the protein degradation and the multiomics initiatives.
Before AstraZeneca, Paola was a key contributor of the Chemical Genetics group at Sanofi Oncology, Cambridge, MA with a focus on phenotypic drug discovery projects for the Wnt and KRAS oncogenic pathways.
Between other responsibilities, Paola is part of the SAB for the Chemical Biology Doctorate Program at Imperial College London and has authored more than 25 peer-reviewed articles.
Paola completed her undergraduate studies in pharmaceutical chemistry and received her Laurea (MSc) at University of Padova, Italy. She then went on to conduct graduate research studies at Imperial College London, UK and postdoctoral studies at UCSD and Boston University.
Lyn Jones
Dana-Farber Cancer Institute, Boston, USA
Lyn Jones completed PhD studies in synthetic organic chemistry at the University of Nottingham, before starting his post-doctorate research at The Scripps Research Institute, California in the area of chemical biology. He joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader, eventually becoming Director of Chemical Biology and Lead Discovery Technologies. He transferred to Pfizer Cambridge, MA to become Head of Rare Disease Chemistry and Head of Chemical Biology, before joining Jnana Therapeutics as Vice President of Chemistry and Chemical Biology. He is currently Chief Scientist at the Center for Protein Degradation at the Dana-Farber Cancer Institute.
He has been recognized with 蹤獲扦 awards for his contributions to HIV, COPD and rare genetic disease research. He has considerable experience working in many other disease areas, including cancer, inflammation, and pain. He is also an elected Fellow of the 蹤獲扦, the Royal Society of Biology, and the Linnean Society, and was most recently recognized as a Fellow of the American Association for the Advancement of Science for his contributions to the field of medicinal chemistry.
Jean-Louis Reymond
University of Bern, Switzerland
Jean-Louis Reymond is a Professor of Chemistry at the University of Bern, Switzerland. He studied Chemistry and Biochemistry at the ETH Zürich and obtained his Ph.D. at the University of Lausanne on natural products synthesis (1989). After a Post-Doc and Assistant Professorship at the Scripps Research Institute, he joined the University of Bern (1997). His research focuses on the enumeration and visualization of chemical space for small molecule drug discovery, the synthesis of new molecules from GDB (http://gdb.unibe.ch), and the design and synthesis of peptide dendrimers and polycyclic peptides as antimicrobials and for nucleic acids delivery. He is the author of > 300 scientific publications and reviews.
